Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

MicroRNAs as regulators of signal transduction in urological tumors.

Fendler A, Stephan C, Yousef GM, Jung K.

Clin Chem. 2011 Jul;57(7):954-68. doi: 10.1373/clinchem.2010.157727. Epub 2011 Jun 1. Review.

2.

Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.

Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T.

Int J Oncol. 2011 Jul;39(1):23-31. doi: 10.3892/ijo.2011.1015. Epub 2011 Apr 26.

PMID:
21523318
3.

DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma.

Hirata H, Hinoda Y, Majid S, Chen Y, Zaman MS, Ueno K, Nakajima K, Tabatabai ZL, Ishii N, Dahiya R.

Cancer. 2011 Apr 15;117(8):1649-60. doi: 10.1002/cncr.25666. Epub 2010 Nov 8.

4.

Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA; European Association of Urology (EAU).

Eur Urol. 2011 Jun;59(6):1009-18. doi: 10.1016/j.eururo.2011.03.023. Epub 2011 Mar 23. Review.

PMID:
21454009
5.

Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis.

Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, Leung HY, Sansom OJ.

Cell Death Dis. 2011 Mar 3;2:e124. doi: 10.1038/cddis.2011.7.

6.

European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update.

Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W.

Eur Urol. 2011 Apr;59(4):584-94. doi: 10.1016/j.eururo.2010.12.042. Epub 2011 Jan 14.

PMID:
21269756
7.

Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy.

Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, Ihn H.

PLoS One. 2010 Dec 14;5(12):e14334. doi: 10.1371/journal.pone.0014334.

8.

Biomarkers in bladder cancer.

Proctor I, Stoeber K, Williams GH.

Histopathology. 2010 Jul;57(1):1-13. doi: 10.1111/j.1365-2559.2010.03592.x. Epub 2010 Jun 23. Review.

PMID:
20579130
9.

Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells.

Choudhary S, Rathore K, Wang HC.

J Cancer Res Clin Oncol. 2011 Mar;137(3):471-80. doi: 10.1007/s00432-010-0910-z. Epub 2010 May 15.

PMID:
20473523
10.

Theranostic and prognostic biomarkers: genomic applications in urological malignancies.

Netto GJ, Epstein JI.

Pathology. 2010 Jun;42(4):384-94. doi: 10.3109/00313021003779145. Review.

PMID:
20438413
11.

Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Pollard C, Smith SC, Theodorescu D.

Expert Rev Mol Med. 2010 Mar 25;12:e10. doi: 10.1017/S1462399410001407. Review.

12.

Clinical experience with survivin as a biomarker for urothelial bladder cancer.

Horstmann M, Bontrup H, Hennenlotter J, Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A, Brüning T.

World J Urol. 2010 Jun;28(3):399-404. doi: 10.1007/s00345-010-0538-2. Epub 2010 Mar 23.

PMID:
20309562
13.

MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells.

Ichimura A, Ruike Y, Terasawa K, Shimizu K, Tsujimoto G.

Mol Pharmacol. 2010 Jun;77(6):1016-24. doi: 10.1124/mol.109.063321. Epub 2010 Mar 18.

14.

MicroRNA control of signal transduction.

Inui M, Martello G, Piccolo S.

Nat Rev Mol Cell Biol. 2010 Apr;11(4):252-63. doi: 10.1038/nrm2868. Epub 2010 Mar 10. Review.

PMID:
20216554
15.

MicroRNAs as potential cancer therapeutics.

Trang P, Weidhaas JB, Slack FJ.

Oncogene. 2008 Dec;27 Suppl 2:S52-7. doi: 10.1038/onc.2009.353. Review.

PMID:
19956180
16.

miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion.

Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW, Kung HF, Lin MC.

Biochem Biophys Res Commun. 2010 Jan 1;391(1):535-41. doi: 10.1016/j.bbrc.2009.11.093. Epub 2009 Nov 24.

PMID:
19931509
17.

miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors.

Ostenfeld MS, Bramsen JB, Lamy P, Villadsen SB, Fristrup N, Sørensen KD, Ulhøi B, Borre M, Kjems J, Dyrskjøt L, Orntoft TF.

Oncogene. 2010 Feb 18;29(7):1073-84. doi: 10.1038/onc.2009.395. Epub 2009 Nov 16.

PMID:
19915607
18.

Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.

Saydam O, Shen Y, Würdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO.

Mol Cell Biol. 2009 Nov;29(21):5923-40. doi: 10.1128/MCB.00332-09. Epub 2009 Aug 24.

19.

Activation of RAS family genes in urothelial carcinoma.

Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA.

J Urol. 2009 May;181(5):2312-9. doi: 10.1016/j.juro.2009.01.011. Epub 2009 Mar 19.

PMID:
19303097
20.

Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.

Wallerand H, Reiter RR, Ravaud A.

Curr Opin Urol. 2008 Sep;18(5):524-32. doi: 10.1097/MOU.0b013e3283097889. Review.

PMID:
18670279
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk